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Abst ra ct
Societal attitudes with respect to mood altering agents have undergone cyclical changes
through A merican history. Cycles if relative tolerance and intolerance affict the perception if
psychotropic drugsfor illicit use, as well as legitimate medical therapy , often creating conf usion
between these two realms. This article examines the relationship between the prevailing social
climate and the subsequent restrictions placed on the use if opiates. H istorical attitudes toward
opiate useserve as a model to explore the current social climate as it pertains to the pharmacologic
treatment ifanxiety. The undertreatment ifanxiety disorders is hypothesized to result largelyfrom
social myths concerning both the nature and treatment ifthese conditions.
Social trends a ppear a nd dis appear in cyclical fash ion , wax ing and waning like
phases of th e mo on. Societ al a tt itudes, fashi on s, a nd t ren ds reflect the collect ive
ideology a nd mo rality of th e masses. It is often possible to generalize a mong man y of
th ese trends; hemline length may be as reflective of the socia l clim ate as a tt itudes
toward psych oactive drugs. U nfort una tely, beca use th is climate do es not di scr imi-
nate, technologic ac hieve me nts, incl ud ing th erapeutic advances in medi cin e, ca n fall
victim to th e collec t ive societal psych e. This principl e is eviden t in the fie ld of clinica l
psychopharmacology. This a r t icle explores changes in pubic percep t ion of psych oac-
tive drugs in ge ne ra l a nd a nt ia nxie ty agents in pa r ticul a r. The relat ion ship bet wee n
public perception of specific pharmacologic agen ts a nd th e abi lit y of ph ysician s to use
ag en ts th a t alte r beh avior, treat somatic pai n, a nd mo du lat e sym pto ms of a nx ie ty
will be ex plored.
Socie tal attitudes with respect to mood alteri ng drugs have un dergone pola r
shifts throughout th e history of Am erica . In th e ninet eenth ce n tu ry, many of th ese
subs tance s, particu larly th e opia te s and cocaine, were conside red beneficia l a nd used
as tonics by a ll segments of soc ie ty. Cocaine a nd morphine were easily availa ble
without prescript ion. The incr easin g awaren ess of t he addictive pot ential of these
drugs eve n tually ca use d a cha nge in public acceptance of narco tics. This decr eased
tolerance of psychot ropi c agen ts bega n in th e la te nineteen th century and re ac he d a
peak in th e early part of thi s ce nt ury ( I) .
The introduction of th e hypodermic needle in th e m id- nine te en th ce ntury was
quickly followed by legislation requiring a pr escription to obtain na rcotics. Public fear
of th ese agen ts increased as did th e numbers of narcot ic-addi ct ed ind ividu als who
12
THE OTHER DRUG WAR 13
used the intravenous route. Also , for th e first time in Am erican hist ory, addiction
became associated in th e public mind with th e health profession. La rge segments of
th e population confused th e legitimat e use of th ese agents to trea t pain with th e
ca re less us e of th ese agents by th e medical profession a nd also wit h illici t us e not
involving ph ysicians. The cavalie r attitude of many ph ysician s with respect to
narcotics ce r ta inly helped to create this perception. Eu gen e O 'Neil d ra mat ized his
mother's physician-assist ed addiction to morphine in his play, "A Lon g Day'sJourn ey
Into Night " (I) .
A complex mixture of political conserva tism, religiou s fundament ali sm, and
decr eased social tol erance was pervasive in th e United States during th e latt er part of
th e ninet eenth and ea rly twentieth cen tury. This climat e of incr easin g conce rn about
mood-alt ering substances, including alcohol, con t r ibute d to th e 1920' s Proh ibiti on.
Additionally, as a result of incr easing public intolerance toward mood- alt ering
substa nces and th e belief that th e health profession was a majo r ca use of addiction ,
th e Harrison Narcotic Act was adopte d in 1914 (I).
The Harrison Act required strict accounting of opium a nd coca importation in to
th e United States, and rigid con t rol of th ese substan ces for medi cal use was
facilitated by a tax levied at eac h transfer point. Permits from th e T reasury
Dep artment had to be obtained by pharmacist s and physicians in orde r to dispense
th ese agen ts. The Harrison Act as originally passed pr ohibited th e mai n tenan ce of
" addict ion" exce pt for specific medical purposes , suc h as pain res ulting from ca nce r
or tuberculosis (I).
A major effec t of th e Harrison Act was th e virtual elim ina t ion of opiat es for
legitimate m edi cal purposes. Treasury agen ts respon sibl e for enforcement of th e
Harrison Act investigated and prosecuted man y ph ysicians who prescr ibed op iates
with missionary-lik e zeal. Between 1915 and 1938, over 25,000 phys icians were
pr osecut ed under the H arrison Act (2) .
During th e 1920s and 1930s, th e use of morphine and heroin declined markedl y
in this coun t ry (I). Unfortunately, no body of data exists to document th e effec ts of
narcotic restriction on patients with severe and chronic pain. It is easy to imagine th e
suffer ing of patients with terminal illn esses wh o were deprived of narcoti c a na lgesics
as a result of th e Harrison Act.
The Harrison Act signifi ed th e height of psychoactive drug intoleran ce in th is
ce n tury. Prohibition was rep ealed in 1933, heralding a change in social a ttitudes.
Following World War II and culmina t ing in th e decades of th e 1960s and 1970s, a
period of relative tol erance towards psychoactive drug use again reign ed in th is
coun t ry (I) . Experimentation with many mood-altering subst an ces such as ca nnabis
and hallucinogens became tacitly permitted in many segm ents of soc ie ty ( I).
In th e 1980s and con tinu ing into th e curre n t decad e, it appears th a t th e
pendulum of tolerance is again swing ing toward blanket disapproval of any psychoac-
tive drug use (2,3,4). It is interesting to note that th e curre nt conserva tive social ,
moral , and political climate parall els th at of th e late nin et eenth ce ntury and ea rly
twentieth ce n tury.
Additional fuel for th e curre nt heighten ed conce rn may s te m from the very real
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problem of "crack" cocaine use. The use of this ag ent , on e of the most physio logically
rewarding substances known, has rea ch ed pandemic proport ion s (5,6) . The public is
con stantly barrag ed with evil associa t ions to this drug, such as crack houses a nd
wid espread cr ime; and in the collective psych e, all "d rugs" (mood-altering sub-
st ances) may become similarly vilified.
When epidemiologic trends of drug abuse are studied, however, it is noted that
consum ption of many of th e mo od-alt ering substances such as alcohol, nicotine,
ca nnabis, a nd cocaine powder have ac tua lly decrea sed in recent yea rs (5,6). Although
use of many of th ese substa nces is on th e wane, th e "d rug wa r" continues to escala te
as if we are facing a narcotic Armageddon, It is est imate d th at as mu ch as $273 billion
a yea r is spe nt to wag e this war, mo stl y related to th e cos ts of arresting and
imprisoning drug users (7). Only a very small proportion of this huge sum of money is
spe nt on addiction re search and substa nce abuse treatment.
Physicians are having an increasingly difficult time using mood-altering agents
as part of medical treatment (3,4,8). The health ca re profession s are again viewed by
societ y as part of the problem . This ph en om enon is reflect ed in reaction s to perceived
misuse of psychotropics by ph ysicians. Examples of th ese reactions may be found in
legislative initiatives, such as triplicate prescription regulations. T hese sanctions
create th e viciou s cycle of physicians unwilling to prescribe certain agen ts , which in
turn causes a relu ctance by needy patients to as k for th em.
Paradoxically, th e under-treatment of severe pain by physicians has re cently
been acknowledged by the Fed eral Government (9) . The Food an d Dru g Administra-
tion issu ed a report in the spring of 1992 ad vocating a more judicious use of narcoti cs
in th e treatment of post ope rat ive pain a nd pain resulting from chronic and terminal
conditions (9). The continued under-treatment of pa in may be a vestige of the
Harrison Act.
An additiona l com pone nt of th e socie tal view of mood altering drugs may st em
fro m th e failure of th e public a nd many physicians to disti nguish between addicti on
a nd dep enden ce. Dep enden ce is a physiological phen omen on whe rein th e presence of
a drug is required to maintain normal fun ctioning. In th e abse nce of the drug,
withdrawal effect s occur and th e underlying dis eas e process may rea pp ea r. Addiction
is dep enden ce coupled with a pathological need to obta in th e drug at any cost (7).
Addicti on is a characterological phen om en on and often resul ts in the drug-seeking
and criminal beh aviors that a re s te reotypica l of th e "addict."
Few people would conside r diab etics to be addict ed to insuli n, alt hough th ey a re
dependent upon this ag ent to maintain normal fun ctioning. Studies have demon-
strate d th at the vast maj ori ty of chro nic pain patients usin g na rcotics for long periods
of time will be abl e to sto p com ple te ly if th e origin of the ir pain is eliminated (3). This
is in marked cont rast to the intraven ou s heroin addic ts who tak e the drug solely for
it s euphoric effec t and will com mit crimes to obtain th eir next " fix."
The dynamics operating between society and health ca re pr oviders and patients
with respect to th e use of psychotropic m edi cation s is difficult to delinea te. It is
evide n t th at a lternating cycles of tolerance a nd intoleran ce comprise the history of
socie tal a tt itude s toward psych oa ctive subs ta nce use in this country. We will now turn
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our attention to th e curre nt social clim a te a nd it s rela tionship to the pharmacologic
treatmen t of anxie ty disorders.
The ex perience of anxiety is a ubiquitous ph en om en on of the human condition.
From an evolu tionary persp ecti ve, fear, a nx ie ty, a nd eve n panic have considerable
surviva l va lue . H owever, wh en anx ie ty or it s physiologic manifestations becom es
severe, unrelenting, and disabling, a person may be face d wit h a serious threat to his
or her health and well being.
The conce pt of distinct anxiet y " diso rde rs" is continua lly changing. The clini cal
manifestations of anxie ty may be described and ca tegorized by many classification
sche mes. Panic dis order is one exa m ple of a distinct clinical a nxie ty syndrome. While
th e te r minology and classification of anx ie ty disorders is qu ite fluid, the extent of
human suffering resulting from th ese ent ities is eas ier to describe and qu antify.
Anxi et y disorders are th e most commo n psychi atric illn esses (I I) . Lifetime pr eva-
len ce of all a nxie ty d isorders, as determined by th e Epidemiologic Catchment Ar ea
survey, ranges from 10.5 to 25 percent. Lifetime prevalen ce for panic disorder is
consis te nt ly about 1.5 percent ( 12).
Research to det ermine th e causes of anxie ty disord ers is taking place rapidly and
involves man y disciplines within psychology, psychi at ry and the bas ic neuroscien ces.
A significan t body of knowl ed ge now exists on th e neu ro ch emical , neuroanatomica l,
and psych odynamic det erminants of anxiety disorders.
As a resul t of th ese varied resea rch effor ts, a sim ilar leap has taken place in th e
th erap eutic approaches to anx iety disorders. Sp ecific pharmacologic ag ents that hav e
anx iolytic ac t ivity have been ava ilable since th e late I 950s . T he tricyclic and mono-
amine oxidase inhibit or a n tide pressan ts and th e ben zodi azepines are all considered
sa fe and effec tive ph a rmacologic treatments for anxiety disorders (13).
Similar advances have tak en place in psychodyna mic psych ot hera pies as well as
cognitive and beh avior al approach es to anxie ty disorders. C urrent state-of-the-art
t reatment of anx ie ty disorders usually involves ph a r macotherapy in combination
with some form of psychotherap y and possibly adjunct ive be haviora l or cognitive
techniques (13). However, curren t est imates sugges t that on ly one-quarter of anxiet y
disorder patients receive a ny form of trea tme nt for th eir dist ress (I I) .
Anxiolyt ic m edi cations, particul arly benzodiazep ines, are a pri mary modality in
th e clinical management of severe a nxiety disorders, ye t rec en t data indicates that
these ag ents, like the opi ates, a re considerably under-u tili zed in clin ical practice
(14,15). It is to this issu e whi ch we will now shift the focus.
Epidemiologic data from th e United St ates Hou seh old Survey on th e use of
Psychotherapeutic Medi cation reveals th at between 1979 and 1990, a significant
decline occurred in th e use of anxi olyti c medi cation s, espec ia lly ben zodi azepines (14).
This decline occurred despite un changed prevalen ce rates for anxiety disorders. It is
clear fr om th e data that thi s decline in usage ca me a t th e ex pe nse of individuals wit h
clini call y significan t a nxie ty disorders. Furthermore, the re has not bee n a shift to th e
use of alte rna tive med ications or non-pharmacologic th era pies du ring this time
period .
Benzodiaz epines have been demonstrated to be safe and effectiv e ag ents for th e
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treatment of both acute and chronic anxiet y disorders ( 15). Desp it e the significant
decline in benzodiazepine pr escriptions a nd availability in th e las t decade, reserva-
tions a bou t th eir con t inue d us e persist a mong ph ysician s a nd the gen eral public ( 15).
The data from several large cross-sect iona l stud ies of ben zodiazepine us e reveal th a t
fears abo u t th e ove ruse a nd abuse of th ese agen ts is greatly exagge ra ted ( 15).
Furthermore, th ese fears may crea te a climate th at may deprive patients of a ppro pri-
a te th erapy.
Approximately I I percent of Am ericans (14 percent of women and 8 percent of
men) have used a benzodiazepine during th e pr eviou s yea r ( 15). These data reflect all
benzodiazepine use, including hypn otics for slee p di sorders. By com pa rison, th e
ove ra ll one -year pr eval en ce for ben zodi azepine use in ot her Western count ries
ranges from a high in Belgium of 17.6 percent to a low of 7.4 percent in th e
Ne the rlands . Only 1.7 percent of th e survey population in the U.S. used benzodiaz-
epines daily for a 12-month period. Two-thirds of th e sa m ple population used th em
daily for less th an on e month 's duration (15). Long-term users were mu ch more likely
than shor t-te r m users to be olde r, have high er levels of psych ic dist ress (us ing
standardi zed sym pto m checklists for anxie ty), and have more somatic symptoms.
Furthermor e, man y " me d ica l" problems were chro nic and severe, su ch as ca rdiovas -
cula r a nd rhe umato log ic cond it ions. " C hro nic" users of benzodiazepines are thus
likely to be a ppro pria te ca nd idates for th e use of th ese age nts ( 15).
Benzodiazepine dependence is strikingly low, given t he large pa t ient population s
who are exposed to th ese ag ents (15). Contrary to popular beli ef, there are fewer
patients abus ing benzodiaz epines th an would be expecte d fro m th e re lative availabil -
it y of th ese agents . Most patients taking a ben zodi azepine for a nxie ty disorder
sym pto ms do not show any sym pto ms of add iction or a buse, and in fact, th e reverse is
true. Lon g-term users of ben zodi azepines usu all y tak e th eir med ication on a n
as -neede d ba sis. There is no evide nce th at chro nic users exhibi t cont inued do se
esca la t ion. Most lon g-term users, in fact , usu all y a t te m pt to see k the lowest effec t ive
dos e to reli eve sym ptoms (15,16) .
Other indicators of abuse, suc h as recr eation al use, visits to m ultiple physicians
see king th e sa me drug, the overwhel ming need to use the drug, or sign ificant
fun cti on al im pairment a re vir t ua lly nonexist ent with benzodiazepine users . One
st udy profiled hospitalized ben zodi azepi ne a buse rs, reveal ing that of 1,347 patients
ad mitted with a subs ta nce abuse di sorder, 136 patients had a primary or secondary
diagnosis ofbenzodiaz epine abuse ( 17). Benzodi az epine a busers were likely to hav e a
secondary Axi s I di agnosis (45 percent) , with depression most common ( 18 percent ) ,
followed by adj us tme n t disorder ( 14 percent ), so matoform disorder (5 percent ) , and
bip olar di sorder (4 percent ). Only 6 percent ofbenzodiazepine abusers misused th ese
agen ts exclus ively ( 17).
The myths a nd misp erceptions regarding th e da ngers of benzodiazepines are
easily understood in view of th e cha ng ing popular a tt it udes and beliefs towards
tranquilizers in our societ y. The results of la rge househ old surveys conducted in 1970
and again in 1979 reveal several striking t re nds : alt ho ug h no change in the perceived
efficacy of th ese agen ts occurred in th e study decad e, th e ge ne ral beli ef th at th ese
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ag ents are unwarranted and over-prescribed becam e more commo n. In 1970, 61
percent of nonuser respondents beli eved that do ctors over-prescr ibed tranqui lizers.
This figure incr eased dramaticall y in 1979 to 83 percent (4).
More people (62 percent) in 1979 agreed with th e sta temen t, " Using t ra nq uiliz-
ers just prevents people from working ou t th eir probl ems for th emselves," than in
1970 (57 percent). More than 80 percent agreed with th e sta te me nt, " It is better to
use willpower to solve problems than it is to use tranquilizers." This figu re remained
relatively constant. Int erestingly, 72 percent of nonuser respondents in 1970 and 1979
agreed with th e statement, "Tranquilizers work very well to mak e a person calm and
relaxed ." In this same study 60 percent of respondents were un willing to condone
tranquilizer use wh en seve re a nxie ty sym ptoms result in a loss of job functioning or
di sruption of family life (4) .
The results of th ese surve ys suggest that a large segme nt of th e popula tion views
anxiety disorders as deficits in charac te r rather than dis ease processes. Parad oxically,
although a majority of th e population believes that anxiolyti c medi cations work well
to alleviate a nxie ty symptoms, th ey are not willing to condo ne their use even in
situa tions of significa nt impairment.
More recent data reveal that th ese trends con t inue, a nd in fact attitudes toward
th e use of benzodiazepines may have become more rigid ( I I) . Pr eval ence rates for
benzodiazepine use con t inue to decline. Many patients whose symptoms merit
pharmacologic treatment simply are not receiving th ese agen ts ( I I) . Eq ua lly d istu rb-
ing is the possibility that many patients wh o have ben efitted from th ese agents in the
pa st may no longer have access to th em a nd a re receivin g neit her alt ernative
medi cation nor non-pharmacologic t reatm ent.
Legi slative effor ts to limit a nd control the pr escript ion of certain psychotropics
are a result of public a tt itudes abou t perceived dangers of these substances . The
impact of regulatory effor ts on physician pr escribing pract ices ca n be st ud ied , a nd
provides an indirect gauge of soci etal attitudes that effec t th e medi cal profession.
InJanuary of 1989, the state of New York issu ed regulation s requiring the use of
triplicat e prescription procedures for th e clinical use of ben zodi azepines (8) . T ripli-
ca te pr escriptions a re required in many states for di sp en sing Sche du le II d ru gs (high
abuse pot ential). With th e Ne w York legislation , ben zodi azepines became th e only
Sch edule IV medi cation (low pot ential for abuse) to requi re such procedures (4).
Contrary to exist ing data , th e New York State Department of Health stated that
benzodiazepines are a major public health problem and cite d this as th e major reason
for th e decision (4).
A recently publish ed study ha s reviewed th e conse q ue nces of th e triplicate
pr escription regul ation s in New York (8) . From 1988 to 1989, pr escri ptions for
benzodi azepines decr eased by 44 percent. However, this decl ine was accompanied by
a marked incr ease in th e us e of less effec tive a nd more dangerou s subst itut es. For
exam ple meprobamate use incr eased by 125 pe rce n t in Ne w York as com pa re d to a
decrease in nation-wide use (-9 percent) during th e study year. Butibarbital
pr escriptions increased by 31 percent versus -1 5 percent nationally (8). Both of these
agents have a high abuse pot ential coupled with an incr eased risk of fatal ove rdose.
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The authors of this study conclude that mandat ed triplicate pr escr iptions of benzodi -
aze pines may result in undertreatment of clinically significant anxiet y. Furthermor e,
many patients with a nxie ty di sorders may receive inappropria te, ineffect ive, and
possibl y dangerou s alte rnatives (8) .
It is clear th at soc ie tal a t titudes ca n have a se r ious nega tive im pact on clinical
practices, especially in th e realm of psychotropi c medi cation s. T he implication s of
this adverse relation ship are stag ge ring. The personal distress resu lt ing from under -
t re a t me n t of pain and anxiety is apparent. The seconda ry effec ts of t his situa tion
suc h as lost productivity, divorce, a nd suicide rat es a re harder to study a nd qu anti fy.
It is distressin g to think that th ese a tt it udes a nd misp ercept ions may ac tually hinder
th e development of new a nd safer psych otropi cs. The consequen ces of intoleran ce are
felt a t a ll levels of socie ty, including in th e ins titut ions and a mo ng scie nt ists
cond uc ti ng pharmacologic research.
W e have seen that societ al misp erception s abo u t the psychotropic effec ts of
analge sic and anxiolytic medications have resulted in undert reatmen t of pai n of
many typ es and th e particul ar psychi c pain related to overw helming a nxie ty. The
relation ship of soc ie tal a tt itudes to th e use of psych ot ro pic ag ents is a subset of the
larger pr obl em of th e hist orical stigmatizat ion of mental illn ess. T his st igmatization
con tinues unabated as we a pproach th e twent y-first ce nt ury. Although we no longer
burn th e insan e a t th e stake , mi sp erception s about the ca use s a nd treatment of
m ental illn ess con t inue tobe rampant. Misinformation a nd ign oran ce with respect to
the nature of psychiatric illn ess and the efficacy of somatic t rea tmen ts for th ese
cond itions will cont inue to result in needless suffer ing .
Ph ysicians ca n help to di sp el th ese myths at a ll levels of socie ty. This ca n only
happen wh en th e m edi cal profession it sel f is read y and willin g to de-stigm at ize
mental illn ess. This process must begin early during med ica l ed uca tion. Only by
incr easing aware ness ca n we hope to end " the other drug war" and use effec tive
medications unhindered and without fear.
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